$TVTX News

Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform

Travere Therapeutics (NASDAQ:TVTX) - High Growth Momentum and Technical Breakout Setup

Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $65

Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61

Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60

Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $65

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines - Slideshow

Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extension Of FILSPARI In Treatment Of Focal Segmental Glomerulosclerosis

Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $62

Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target

HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $67

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

Travere Therapeutics Enters Into Exclusive Licensing And Collaboration Agreement With Everest Medicines For Development And Commercialization Of Civorebrutinib

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

Travere Therapeutics Receives Notice Of Allowance From U.S. Patent And Trademark Office For Patent Titled Biphenyl Sulfonamide Compounds For The Treatment Of Kidney Diseases Or Disorders

Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters